Child Diabetes (Type 1) — Symptoms, Insulin Therapy & Management Guide — Symptoms, Causes & Treatment | MyMedicPlus

Diabetes in children predominantly refers to Type 1 diabetes mellitus (T1DM), an autoimmune condition where the body's immune system destroys the insulin-producing beta cells of the pancreatic islets of Langerhans. Without insulin — the hormone essential for glucose transport into cells — blood glucose levels rise dangerously (hyperglycaemia). Type 1 diabetes affects approximately 1.2 million children globally, with an incidence increasing by 3-5% annually. It typically presents between ages 4-16, though it can occur at any age. Children with T1DM require lifelong insulin therapy to survive. Type 2 diabetes in children (associated with obesity) is also increasing, particularly in adolescents. Type 1 diabetes accounts for 85-90% of diabetes in children under 15 years. Type 2 diabetes in children, once rare, now accounts for up to 15-20% of new adolescent diabetes diagnoses in high-income countries — driven by the childhood obesity epidemic. Both types require expert paediatric diabetological care with structured family education, glucose monitoring, and multidisciplinary team support.

Type 1 diabetes is an autoimmune disease caused by T-cell-mediated destruction of pancreatic beta cells, leading to absolute insulin deficiency. The precise trigger is unknown but involves genetic susceptibility (HLA-DR3/DR4 and HLA-DQ alleles account for 50% of genetic risk) plus environmental factors (viral infections — Coxsackievirus B, EBV; vitamin D deficiency; gut microbiome changes; early cow's milk introduction; and reduced childhood infection exposure). Family history is a risk factor (5% risk if one parent has T1DM; 30% if both parents have it). Nordic countries (Finland, Sweden) have the highest incidence worldwide. Monogenic diabetes (MODY — maturity-onset diabetes of the young) accounts for 1-2% of childhood diabetes, caused by single-gene mutations (HNF1A, GCK, HNF4A) — often misdiagnosed as Type 1 or Type 2. Correct diagnosis with genetic testing allows targeted oral sulfonylurea treatment rather than insulin therapy in HNF1A and HNF4A MODY.

Classic presentation ('the 4 Ps'): polyuria (frequent urination, bedwetting in previously dry children), polydipsia (excessive thirst), polyphagia (increased hunger), and weight loss (body breaks down fat and muscle for energy). Additional symptoms: fatigue and lethargy, blurred vision (osmotic lens changes), recurrent thrush or urinary tract infections, irritability and poor school performance, and fruity/acetone breath (from ketosis). Diabetic ketoacidosis (DKA) at presentation is common in younger children (20-30% present in DKA): severe vomiting, abdominal pain, rapid deep Kussmaul breathing, dehydration, confusion, and coma — a medical emergency requiring immediate hospitalisation. Enuresis (bed-wetting) in a previously continent child is an important early warning sign of Type 1 diabetes — the osmotic diuresis from glycosuria causes overnight polyuria exceeding bladder capacity. Recurrent candidal nappy rash or oral thrush in an infant may similarly be an early indicator of undiagnosed hyperglycaemia.

Diagnosis in a child with classic symptoms requires a single random blood glucose above 11.1 mmol/L (200 mg/dL). In asymptomatic children, two readings of fasting glucose above 7.0 mmol/L (126 mg/dL) or HbA1c above 48 mmol/mol (6.5%) are required. Urine dipstick testing shows glycosuria and ketonuria. Blood ketones (beta-hydroxybutyrate above 3.0 mmol/L) confirm significant ketosis/DKA. Antibody testing (anti-GAD, anti-IA2, anti-ZnT8, anti-insulin antibodies) confirms autoimmune aetiology, differentiating T1DM from Type 2 diabetes or MODY (maturity-onset diabetes of the young). C-peptide levels (low or undetectable) reflect residual beta cell function and distinguish T1DM from Type 2. Continuous glucose monitoring (CGM) has become the standard of care for monitoring glycaemia in children with T1D in high-income countries — NHS England now funds Libre 2 or Dexcom G7 for all children and young people with T1D, replacing the majority of fingerprick blood glucose testing.

All children with Type 1 diabetes require insulin therapy — there is no oral medication that can replace it. Insulin regimens: basal-bolus regimen (multiple daily injections — long-acting background insulin once or twice daily plus rapid-acting insulin with each meal, adjusted for carbohydrate content); or continuous subcutaneous insulin infusion (CSII — insulin pump) which delivers precise continuous insulin. Carbohydrate counting — matching insulin dose to carbohydrate intake — is the standard approach for meal management. Blood glucose monitoring (BGM): multiple daily fingerprick blood tests to guide insulin dosing. Continuous glucose monitoring (CGM): real-time interstitial glucose sensing devices (Libre, Dexterity, Dexcom G7) reduce fingerprick tests, improve HbA1c, and reduce hypoglycaemia; hybrid closed-loop systems (artificial pancreas — CGM + pump) automate basal insulin delivery. HbA1c target: below 48 mmol/mol (6.5%) minimises complication risk. Hypoglycaemia management: fast-acting glucose (Lucozade, glucose tablets, Glucogel) for mild-moderate hypoglycaemia; glucagon injection or nasal glucagon (Baqsimi) for severe hypoglycaemia with loss of consciousness.

Diabetic ketoacidosis (DKA) is an acute life-threatening complication of untreated or undertreated T1DM — associated with a mortality rate of 0.3-0.5% in children and risk of cerebral oedema (swelling of the brain — the most serious DKA complication in children). Long-term complications from chronic hyperglycaemia (HbA1c consistently above target) develop after 5-15 years of poorly controlled diabetes: diabetic retinopathy (leading cause of blindness in working-age adults), nephropathy (chronic kidney disease), peripheral neuropathy (pain, numbness in feet), autonomic neuropathy, and cardiovascular disease. Each 1% reduction in HbA1c reduces microvascular complication risk by 35% (DCCT trial).

Type 1 diabetes cannot currently be prevented. Research into immune modulation (anti-CD3 antibody teplizumab delays T1DM onset in high-risk relatives by 2 years) offers future preventive potential. For managing T1DM in children: educate the child (age-appropriately) and all carers about insulin injection technique, blood glucose targets, carbohydrate counting, hypoglycaemia recognition and treatment, sick day rules, and when to call the diabetes team. Inform school staff — provide a healthcare plan with glucose monitoring schedule, insulin administration instructions, hypoglycaemia treatment, and emergency contact. Regular physical activity improves insulin sensitivity but requires glucose monitoring before, during, and after exercise (risk of exercise-induced hypoglycaemia). Ensure emotional support — living with T1DM increases anxiety, depression, and diabetes burnout risk in children and adolescents.

Seek emergency care immediately for a child with: extreme thirst, excessive urination, unexplained weight loss, abdominal pain, vomiting, fruity-smelling breath, drowsiness, or confusion — these are the classic symptoms of diabetic ketoacidosis (DKA) in new-onset Type 1 diabetes. DKA is life-threatening and requires urgent hospital admission. Do not wait for a GP appointment. If a known diabetic child is unconscious, fits, or unresponsive, call emergency services immediately — give buccal glucose gel if the child is conscious and able to swallow. See a paediatrician urgently for: any child with a family history of Type 1 diabetes and increasing urinary frequency, polyuria, or weight loss. Contact the diabetes team for: unexplained high glucose readings, repeated hypoglycaemia, ketones on home testing, or any illness causing inability to eat in an insulin-treated child.